May 29, 2020
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020
Apr 10, 2020
Global Pharma Giant Eisai Leads a $6M Series Seed Investment Round in Darmiyan to Expedite its Clinical Market Entry
Mar 09, 2020
Global Osteoporosis Therapeutics Industry Insights, 2012-2025 - Bisphosphonates Will Bring in Healthy Gains of >$6.9 Billion by 2025
Feb 13, 2020
Eisai to Voluntarily Withdraw BELVIQ®/BELVIQ XR® in the U.S.
Dec 17, 2019
BioArctic Announces Research Collaboration with Eisai Regarding BAN2401
Dec 10, 2019
Eisai Presents New Analyses of Potential Blood-Based Alzheimer's Diagnostic Test and Lemborexant as Potential Sleep-Wake Disorder Therapy
Dec 05, 2019
BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease
Dec 02, 2019
Eisai and Biogen's Joint Investigational Asset BAN2401 Data to be Presented at Clinical Trials on Alzheimer's Disease Conference
Dec 02, 2019
BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference
Nov 28, 2019
Analysis on the World Alzheimer's Therapeutics Market 2019-2025 - Eisai Co, Novartis, Pfizer, Eli Lilly & Company, and Johnson & Johnson are Dominating
Sep 24, 2019
Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019
Sep 13, 2019
Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Sep 09, 2019
SpePharm AG Wins Case Against Eisai Inc. in United States District Court for District of Delaware
Aug 26, 2019
Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc.
Jul 18, 2019
BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019
Jul 15, 2019
BioArctic's Co-Founder Received AAIC Lifetime Achievement Award
Jul 11, 2019
New Data in 2 Oral and 13 Poster Presentations about Eisai's Latest Dementia Pipeline, Including BAN2401, Elenbecestat and Lemborexant, to be Presented at Alzheimer's Association International Conference
Jul 11, 2019
BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 2019
May 29, 2019
Adriana Herrera Appointed Senior Vice President, Americas Commercial Oncology at Eisai Inc.
May 20, 2019
BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease